SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Flannery O'Connor — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFlannery O'Connor
Date of birth1925-03-25
IdentifiersMRN HR-ML046-SYN-TD; SSN (made up) 000-46-1853
Document date1950-04-29
AuthorAugusta Pemberton-Diallo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Kidney biopsy result and start of treatment. [S]

History of Present Illness

Ms. O'Connor had an ultrasound-guided kidney biopsy five days ago without bleeding. It shows ISN/RPS class III (A) lupus nephritis: focal endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, with no crescents or thrombotic microangiopathy. She heard the result from Dr. Okonjo-Strand by telephone two days ago, as she had asked, and again in full today. A levonorgestrel intrauterine system was inserted yesterday. Her joints and rash are unchanged; she has taken hydroxychloroquine and losartan for a week. Today she has the first of three methylprednisolone infusions, starts mycophenolate, and learns to give herself belimumab. She asked how to keep her mornings for writing through treatment. [S]

ElementDetail
BiopsyClass III (A) lupus nephritis; activity 6 of 24, chronicity 1 of 12
ContraceptionIntrauterine system inserted yesterday
TodayMethylprednisolone 500 mg (first of three); mycophenolate; first belimumab injection
BoneDXA today

Review of Systems

SystemResultFinding
ConstitutionalPositiveFatigue; low-grade fevers in the evenings
MusculoskeletalPositiveHand and knee pain and swelling unchanged; no hip or groin pain
IntegumentaryPositiveFacial rash unchanged
GenitourinaryNegativeNo pain at the biopsy site; no blood clots in the urine
PsychiatricNegativeDetermined; sleeping adequately

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route1950-04-13activeS
Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long termOne tablet once dailyOral route1950-04-22activeS
Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressureOne tablet once dailyOral route1950-04-22activeS
Methylprednisolone 500 mg intravenous infusion once daily for three daysOne infusion daily for three daysIntravenous route1950-04-29 to 1950-05-01completedS
Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six monthsOnce daily, taperingOral route1950-04-29activeS
Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice dailyTwo tablets twice dailyOral route1950-04-29activeS
Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weeklyOnce weekly by self-injectionSubcutaneous route1950-04-29activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route1950-04-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1950-04-29Body height168cmS
1950-04-29Body weight59.8kgS
1950-04-29Body mass index (BMI) [Ratio]21.2kg/m2S
1950-04-29Systolic blood pressure128mm[Hg]S
1950-04-29Diastolic blood pressure80mm[Hg]S
1950-04-29Heart rate84/minS
1950-04-29Respiratory rate14/minS
1950-04-29Body temperature37CelS
1950-04-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1950-04-29Hemoglobin [Mass/volume] in Blood11.2g/dL12-15.5 g/dLLowS
1950-04-29Leukocytes [#/volume] in Blood by Automated count3.610*3/uL4-11 10*3/uLLowS
1950-04-29Lymphocytes [#/volume] in Blood by Automated count0.910*3/uL1-4.8 10*3/uLLowS
1950-04-29Platelets [#/volume] in Blood by Automated count15110*3/uL150-400 10*3/uLNormalS
1950-04-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L<=33 U/LNormalS
1950-04-2925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma26ng/mL30-100 ng/mLLowS
1950-04-29DXA Lumbar spine [Z-score] Bone density-0.4{Z-score}Z-score above -2.0 is within the expected range for ageNormalS
1950-04-29DXA Femur [Z-score] Bone density-0.2{Z-score}Z-score above -2.0 is within the expected range for ageNormalS

Physical Exam

Vital signs recorded on 1950-04-29; see the Vital Signs section. [S]

SystemFinding
GeneralTired, composed; temperature 37.0 °C
BackBiopsy site clean and healing; no tenderness
SkinMalar rash as before
MusculoskeletalSynovitis of the hands and wrists as before; full painless hip movement
CardiovascularNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be establishedresolvedconfirmed M25.50S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D).
Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be establishedresolvedconfirmed R80.9S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit.
Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negativeactiveconfirmed M32.19S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used.
Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney functionactiveconfirmed M32.14S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used.
Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or lessactiveconfirmed Z79.52S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low.
Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in placeactiveconfirmed Z79.624S — Synthetic treatment status.
Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatmentactiveconfirmed Z97.5S — Synthetic contraception, chosen by the patient.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingKidney biopsyBefore treatmentUp to dateClass III (A); activity 6 of 24; chronicity 1 of 12
Medication safetyPulse methylprednisolone and oral taper planAt the start of treatmentCompleted today500 mg today and for two more days; written taper schedule given
LaboratoryBlood count and liver tests before mycophenolateBefore the first dose, then weekly for a month, twice monthly for two months, then monthlyCompleted todayWhite cells 3.6, lymphocytes 0.9, hemoglobin 11.2, platelets 151; ALT 18
Medication safetyPregnancy test and contraception before mycophenolateBefore the first doseCompleted todayPregnancy test negative; intrauterine system inserted yesterday
Medication safetyBelimumab start and injection teachingAt the startCompleted todayFirst 400 mg dose given under supervision; she injected herself; warned to report low mood
ImagingBone density (DXA) at the start of glucocorticoidsAs soon as possible after startingCompleted todayLumbar spine Z-score -0.4; femoral neck Z-score -0.2
Laboratory25-hydroxyvitamin DAt the start of glucocorticoidsCompleted today26 ng/mL; vitamin D3 started
ExaminationAvascular necrosis symptomsEvery visitCompleted todayNo hip, groin, or knee pain; full hip movement
Medication safetyHydroxychloroquine baseline eye examinationWithin the first yearOrderedOphthalmology booked in two months
LaboratoryPotassium and creatinine after starting losartan2 to 4 weeks after startingDueLosartan started a week ago; to be drawn with the blood counts in two weeks
ExaminationBlood pressureEvery visitCompleted today128/80 mmHg on losartan
LaboratoryUrine protein-to-creatinine ratio, sediment, creatinine, anti-dsDNA, and complementsEvery 3 months during active treatmentDueAt three months
Medication safetyRecombinant zoster vaccine dose 21 to 2 months after dose 1DueAt the three-month visit
Self-managementWriting life and treatment scheduleEvery visitCompleted todayInfusions booked in the afternoons; injections at home

Goal progress:

Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022); BENLYSTA (belimumab): prescribing information (subcutaneous dosing for lupus nephritis) (2026); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026)

Follow-up: Methylprednisolone tomorrow and the day after. Rheumatology blood counts weekly. Ophthalmology in two months. Three-month review. Next scheduled visit 1950-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. [S]